CLINICAL_TRIALS
trial_result
· 2024-09-26
Clinical Trial Update: QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]
Summary
A Phase 1 study of N-803 in relapsed or refractory multiple myeloma was terminated; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Altor BioScience | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1 | Status: TERMINATED | Results posted: 2024-09-26